Drug Profile
SGM 201
Alternative Names: SGM-201Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator SurgiMAb
- Class Antibody diagnostics; Diagnostic conjugates; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Ovarian cancer (Diagnosis) in France (unspecified route)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Ovarian-cancer(Diagnosis) in France
- 16 May 2016 Preclinical trials in Ovarian cancer (Diagnosis) in France